%0 Journal Article %T Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? %A Metro, Giulio %A Di Maio, Massimo %J Translational Lung Cancer Research %D 2018 %B 2018 %9 %! Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? %K %X Targeted treatment with a tyrosine kinase inhibitor (TKI) is associated with high response rates and significantly prolonged progression-free survival in the minority of patients (approximately 15–20%) with advanced non-small cell lung cancer (NSCLC) whose tumor harbors an epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) rearrangement or ROS1 rearrangement (1). %U https://tlcr.amegroups.org/article/view/23047 %P S290-S293 %@ 2226-4477